Key Points:
·Introducing the "National Priority Review Mechanism": reducing the drug review timeline from 10-12 months to 1-2 months.
·Crackdown on illegal e-cigarettes: Customs agencies jointly seize nearly $34 million worth of illegal e-cigarette products.
·Crackdown on Cost Data: Investigating Chinese third-party testing agencies for falsifying data to maintain the scientific integrity of the evaluation process.
·Advancing AI Deployment: Completing the first AI-assisted review pilot and launching an internally developed generative AI tool named "Elsa" to modernize the review process.
·Transparent governance: Establishing the "FDA Direct" public communication platform, releasing future agendas, and attempting to disclose drug approval letters in order to achieve a higher level of transparency in governance.
【2Firsts News Flash】According to the US FDA on July 10th, FDA Commissioner Marty Makary released a statement on his 100th day in office, reviewing the agency's progress under the bipartisan framework of "Make America Healthy Again." He emphasized the core principles of "science, transparency, and common sense," and highlighted the achievements of the FDA, including accelerating drug approval processes, cracking down on illegal e-cigarettes, strengthening consumer protection, promoting the use of AI, increasing transparency in FDA decision-making processes, and working towards modernizing the FDA.
The following is an excerpt from the full statement:
·The national priority review mechanism - announced a pilot program that, after submitting the final application, shortens the drug review process from 10-12 months to 1-2 months.
·These applications are aimed at addressing national priorities in the United States, such as responding to major health crises or unmet public health needs, increasing domestic drug production, and providing more innovative treatment options for the American people.
·Crackdown on illegal e-cigarettes - working with U.S. Customs and Border Protection, seized nearly $34 million worth of illegal, youth-attracting e-cigarette products originating from China.
·Strict crackdown on data falsification - discovered that a Chinese third-party testing company was producing fake or invalid data; taking swift action to protect the integrity of premarket application processes and medical device supply chains.
·AI-assisted review - successfully completed the first AI-assisted scientific review pilot, demonstrating that internal AI tools can significantly reduce the time reviewers spend on daily tasks or non-productive busy work.
·Equipping reviewers with internal AI tools - launched Elsa, a generative AI tool designed to help all FDA staff (from scientific reviewers to researchers) work more efficiently. Elsa is just the first step in the FDA's grand plan to integrate AI into agency processes.
·Establishing a better adverse event reporting database - launched a comprehensive initiative to integrate disparate adverse event reporting databases, making post-market drug monitoring more effective.
·Transparent communication - created FDA Direct, a channel for regular direct communication with the public, through frequent, informal dialogues with the FDA Commissioner to understand strategic updates and key agency decision-making.
·Transparent agenda - The Journal of the American Medical Association clearly outlines the FDA leadership's priorities for modernizing and improving the agency in the coming months.
·Transparent decision-making - starting to publicly disclose decision letters issued for new drug and biologic product applications.
Finally, McClellan stated that the FDA will uphold the gold standard of science, thorough transparency, and common sense, dedicated to providing the American people with safer food, more timely treatment, and more trustworthy regulation.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
